Abstract
Objective. To estimate efficiency and safety of remdesivir in treating new coronavirus infection in pregnant. Materials and methods. A retrospective cohort study including 61 medical patient’s records who underwent COVID-19 and being pregnant more than 20 weeks was conducted. Medical case histories were divided into 2 groups: the main one with the use of remdesivir treatment (n = 35) and control one (n = 26) without it. The groups were representative by age, anthropometric data and comorbidity (p > 0.05). Results. The use of remdesivir in pregnant patients with COVID-19 causes a reduction in fever by 15% and achievement of target saturation values in 94.3% of cases, reduces С-reaction protein (CRP) levels by 3.5 times, D-dimer by 2.6, Lactat Dehydrogenase (LDG) by 1.4 times on 5th day from the moment of hospitalization, reduces its duration by 30.8%, does not affect the course of pregnancy and the frequency of Cesarean section. Conclusion. The use of remdesivir in the treatment of COVID-19 in pregnant patients with a gestation period of more than 20 weeks is effective, as evidenced by the shortening of the fever period, the duration of hospitalization, improving oxygenation, reduction of laboratory markers "cytokine storm" in blood levels and safe due to the lack of impact on pregnancy and delivery strategy. Key words: СOVID-19, cytokine storm, laboratory criteria, pregnancy, remdesivir
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
